Core Viewpoint - The company, Huili Pharmaceutical, announced plans to jointly invest in a new private equity fund focused on the biomedical sector, particularly targeting late-stage clinical projects with clear commercial potential [1] Group 1: Investment Details - Huili Pharmaceutical will collaborate with Hangzhou Xiaochi Private Equity Fund Management Co., Ltd. to establish Chengdu Huili Xiaochi Biomedical Venture Capital Partnership (Limited Partnership) [1] - The initial subscription scale of the private equity fund is set at 400 million yuan, with Huili Pharmaceutical committing 150 million yuan, representing 37.5% of the total initial subscription amount [1]

Core Viewpoint - The company, Huili Pharmaceutical, announced its plan to establish a private equity fund focused on the biomedical sector, particularly targeting late-stage clinical projects with clear commercial potential [1] Group 1: Investment Details - Huili Pharmaceutical will collaborate with Hangzhou Xiaochi Private Fund Management Co., Ltd. and Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. to set up the Chengdu Huili Xiaochi Biomedical Venture Capital Partnership [1] - The initial subscription scale of the private equity fund is set at 400 million yuan, with Huili Pharmaceutical committing 150 million yuan, representing 37.5% of the total initial subscription amount [1]